Researchers have identified that cell cycle quiescence in haematopoietic progenitor cells underpins primary resistance to azacitidine in patients with myelodysplastic syndrome. The knowledge could help identify a method of determining non-responders earlier than the current ‘wait and see’ approach which results in some patients receiving futile treatment for four to six months. The research also ...
Cells need to wake up to treatment for myelodysplastic syndrome
26 Jul 2017